VivoSeq
Other

Crigler-Najjar Syndrome

4

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Crigler-Najjar syndrome is an early-stage landscape with 4 programs across 1 company. The most active players are Hansa Biopharma AB.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hansa Biopharma AB

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical1

Orlistat

Engelhard Arzneimittel GmbH & Co.KG

Phase 1
No programs
Phase 23

Imlifidase

Hansa Biopharma AB

Hepastem

Cellaion SA

GNT0003

Genethon

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSProtein / enzyme125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)
Completed·CCellaion SA·Phase 1/2·NCT01765283·20 enrolled
Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
Recruiting·GGenethon·Phase 2·NCT06518005·3 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)